title: VEGF target in HHT lung patients: the role of bevacizumab as a possible alternative to embolization.
authors.forename: Alexis
authors.initials: A
authors.lastname: Lacout
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Marcy
authors.forename: Juliette
authors.initials: J
authors.lastname: Thariat
authors.forename: Mostafa
authors.initials: M
authors.lastname: El Hajjam
authors.forename: Pascal
authors.initials: P
authors.lastname: Lacombe
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001165:Arteriovenous Malformations / Q000235:genetics / Q000628:therapy; D000068258:Bevacizumab; D004621:Embolization, Therapeutic; D006801:Humans; D008168:Lung / Q000098:blood supply; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000235:genetics / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab